In this study, comprehensive genomic profiling (CGP) was used to evaluate the frequency of NF2 genomic alterations in histologic subtypes of kidney tumors and co-occurring genomic alterations in other genes and biomarkers. This evidence concerns the gene NF2 and kidney neoplasm.